Down-regulated VEGF expression in the diabetic heart is normalized by an endothelin ETA receptor antagonist.
Recently, down-regulation of vascular endothelial growth factor (VEGF) in the heart was suggested as a potential molecular explanation for the increased risk of cardiovascular morbidity and mortality in patients with diabetes. Increased endothelin-1 production is reported in diabetes. Here, we report that down-regulated VEGF expression in the diabetic rat heart is normalized by an endothelin ETA receptor antagonist, suggesting that endothelin antagonism may be a novel therapeutic strategy for diabetic heart.
Jesmin
Subrina
S
Cardiovascular Division, Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
Miyauchi
Takashi
T
Goto
Katsutoshi
K
Yamaguchi
Iwao
I
D000704:Analysis of Variance; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000235:genetics* / Q000473:pathology / Q000517:prevention & control; D015536:Down-Regulation / Q000187:drug effects / Q000235:genetics; D065130:Endothelin A Receptor Antagonists; D015870:Gene Expression / Q000187:drug effects*; D006352:Heart Ventricles / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D011743:Pyrimidines / Q000494:pharmacology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013449:Sulfonamides / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*
D065130:Endothelin A Receptor Antagonists; D011743:Pyrimidines; D012333:RNA, Messenger; D013449:Sulfonamides; C113972:T 0201; D042461:Vascular Endothelial Growth Factor A